The pharmaceutical industry has faced increasing scrutiny due to its involvement in criminal activities, including fraud, regulatory violations, price-fixing, and unethical clinical trial practices. This study explores the intersection of criminal law and pharmaceutical misconduct in the United States, focusing on legal frameworks governing corporate liability, enforcement mechanisms, and judicial outcomes. Utilizing a systematic review of federal and state litigation records, legal settlements, and regulatory reports, we examine key cases prosecuted under the False Claims Act, the Controlled Substances Act, and the Anti-Kickback Statute. Between 1991 and 2021, pharmaceutical companies paid over 62. 3 billion in legal penalties, with opioid-related offenses constituting a significant portion of recent settlements. Despite these penalties, corporate recidivism remains prevalent, highlighting deficiencies in deterrence strategies and legal enforcement. This study further discusses evolving legal doctrines, including the application of the Responsible Corporate Officer Doctrine, which seeks to hold executives criminally liable for regulatory violations. Our findings emphasize the need for stricter legal accountability, enhanced whistleblower protections, and the potential for criminal sanctions against individual executives to address persistent pharmaceutical crimes. This research contributes to the broader discourse on corporate criminal liability and public health protection through legal reform.
Roger Sahni (Wed,) studied this question.